INS and type 2 diabetes mellitus: When taken with reports that Stxbp1 expression is reduced in islets from patients with type 2 diabetes, as well as from the Goto-Kakizaki rat model of type 2 diabetes (52, 58, 59), these findings suggest Stxbp1 as a potential target to enhance not only insulin secretion, but also GLP-1 release.